Circio Holding ASA
OSE:CRNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Circio Holding ASA
Capital Expenditures
Circio Holding ASA
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Capital Expenditures
-kr189k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Capital Expenditures
-kr20.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-6%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Capital Expenditures
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Capital Expenditures
-kr3.6m
|
CAGR 3-Years
34%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-9%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Capital Expenditures
-$38k
|
CAGR 3-Years
76%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Capital Expenditures
-kr73.1m
|
CAGR 3-Years
-555%
|
CAGR 5-Years
-133%
|
CAGR 10-Years
-47%
|
|
Circio Holding ASA
Glance View
Circio Holding ASA is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. The company is headquartered in Lysaker, Akershus and currently employs 21 full-time employees. The company went IPO on 2014-06-16. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
See Also
What is Circio Holding ASA's Capital Expenditures?
Capital Expenditures
-189k
NOK
Based on the financial report for Jun 30, 2025, Circio Holding ASA's Capital Expenditures amounts to -189k NOK.
What is Circio Holding ASA's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-1%
